Quantum-Si (QSI) Incorporated announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute. In the pre-print titled “Heterologous expression of the human cohesin complex in Saccharomyces cerevisiae results in a dominant-negative phenotype”, the researchers expressed key human chromosome-organizing proteins in yeast cells. They hypothesized that the human cohesins were forming complexes and disrupting the activity of endogenous yeast cohesins. This matters for cancer drug development because problems with cohesin can drive genome instability in tumors, pointing to new ways to target cancer cells. “We are excited to see the first manuscript published by international researchers,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “In this study, single-molecule protein sequencing enabled the researchers at University of British Columbia and B.C. Cancer Research Institute to directly identify hybrid cohesin complexes, demonstrating the value of our technology as a foundational tool for mechanistic biology research and therapeutic discovery.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QSI:
- Quantum-Si announces customer samples tested on Proteus prototype system
- Quantum-Si, Jabil, Five Below, Ross, Darden Shock
- Quantum Leap: IBM teams with Signal and Threema on quantum-safe messaging
- Quantum‑Si Bets On Proteus In Pivotal Earnings Call
- Quantum-Si: Buy Rating Backed by Proteus Differentiation, Disciplined Capital Use, and Strong Commercial Readiness for 2026 Launch
